

Redeye Interview with CEO Hanna Sjöström

Following the release of Neola Medical's Q4 2024 report, Redeye Equity Research Analyst Gustaf Meyer interviewed CEO Hanna Sjöström to discuss key takeaways, the company's progress toward the clinical phase, and the upcoming first clinical study on preterm born babies in Sweden.

Watch the full interview here: [Redeye Interview with CEO Hanna Sjöström](#)

Redeye also provided a research update, including a strengthened fair value range for Neola Medical.

Access the interview and additional insights from Redeye here: <https://www.redeye.se/company/neola-medical>

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Image Attachments

[Redeye Interview With CEO Hanna Sjöström Following The Q4 Report 2024](#)

Attachments

[Redeye Interview with CEO Hanna Sjöström](#)